Third and fourth-generation GLP-1 agonists represent a significant advancement in addressing the crisis of overabundance and are a leading frontier in biotech for anti-sarcopenia drugs.

“And I think pharmarmacologically, for what it's worth, I think that's the next frontier, right? So I think what the GLP1 agonists have done over the past 5 years um with the introduction of the the third and fourth generations of those drugs, the first two were largely failures, but because of how successful the third and fourth generations were, um we're really at a point where I think people can see that you can address the uh crisis of overabundance from a nutrition standpoint, but what people realize the new problem that is yet to be unressed is sarcopenia. And when I'm looking at what's at the leading edge in the frontier of biotech right now, it's all around anti-arcopenia drugs.”